Welcome to our dedicated page for Astera Labs SEC filings (Ticker: ALAB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Astera Labs's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Astera Labs's regulatory disclosures and financial reporting.
Michael Truett Tate, Chief Financial Officer of Astera Labs, reported multiple transactions in the issuer's common stock on August 7–8, 2025. The filing discloses a total of 278,373 shares sold across several block transactions with reported weighted-average prices of $169.608, $170.3396, $171.4778 and $173.8234, and price ranges noted between $169.05 and $174.04. The report also records bona fide gifts of 7,500 shares to the GlobalStar DAF and 10,000 shares to a non-affiliated person.
The filing shows indirect ownership through the Tate 1997 Living Trust and GlobalStar DAF and disclaims direct beneficial ownership beyond any pecuniary interest. Following the reported transactions, the Tate Trust's reported indirect holdings are shown as 501,496 shares. Footnotes state the seller will provide details on the number of shares sold at each separate price upon request.
Gajendra Sanjay, President and COO of Astera Labs (ALAB), reported automated sales under a Rule 10b5-1 plan adopted November 30, 2024. On 08/07/2025 he sold a total of 280,000 shares in multiple transactions at prices ranging approximately from $165.17 to $175.00. Following the sales, the filing shows Trust 1 holds 5,525,545 shares, Trust 2 and Trust 3 each hold 695,000 shares, and the reporting person directly holds 2,262,318 shares. The filing disclaims beneficial ownership of the trust-held shares except for any pecuniary interest, and the reporting person offers to provide transaction-level price details on request.
Astera Labs' Form 144 discloses a proposed sale of 26,000 common shares on NASDAQ through broker Stifel, with an aggregate market value of $4,556,737.00 and the issuer reported 162,150,000 shares outstanding. The filing shows the shares were acquired in private placements: 1,000 on 05/17/2022 and 25,000 on 11/08/2019. A related sale by Stefan A Dyckerhoff of 26,000 shares on 08/07/2025 for $4,508,959.00 is also listed. The notice includes the seller's representation that they do not possess undisclosed material adverse information and contains the standard legal warning about intentional misstatements.